Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects

Shining Wang1 | Grace Chen1 | Emilio Merlo Pich2 | John Affinito3 | Michael Cwik4 | Hélène Faessel1

1Quantitative Clinical Pharmacology, Takeda Pharmaceuticals International Co, Cambridge, Massachusetts, USA
2Clinical Science, Takeda Pharmaceuticals International AG, Zurich, Switzerland
3Patient Safety Evaluation, Takeda Pharmaceuticals, Deerfield, Illinois, USA
4Clinical Biomarker Innovation and Development, Takeda Pharmaceuticals, Cambridge, Massachusetts, USA

Correspondence
Hélène Faessel, Neuroscience Therapeutic Area Unit, Takeda Pharmaceuticals International Co. Cambridge, MA 02139, USA. Email: helene.faessel@takeda.com

Funding information
Takeda Pharmaceutical Company, Ltd

Aims: Soticlestat is a first-in-class selective inhibitor of cholesterol 24-hydroxylase, the enzyme that converts brain cholesterol to 24S-hydroxycholesterol (24HC), a positive allosteric modulator of N-methyl-D-aspartate receptors. Soticlestat is under development as treatment for rare developmental and epileptic encephalopathies.

Methods: In this first-in-human study, 48 healthy men and women received single ascending doses of soticlestat oral solution or placebo. Subsequently, nine healthy subjects received soticlestat tablets under fed and fasting conditions to assess the relative oral bioavailability and effects of food. Serial blood and urine samples were collected for pharmacokinetic and pharmacodynamic assessments.

Results: Soticlestat appeared to be well tolerated up to a single dose of 1350 mg. Adverse events (AEs) were mild in intensity, and dose-dependent increase in AE prevalence was not apparent. Soticlestat administered via oral solution was rapidly absorbed (median time to maximum plasma concentration [\(C_{\text{max}}\]) 0.250–0.520 h). Mean \(C_{\text{max}}\) and area under plasma concentration–time curve from zero to infinity increased by 183- and 581-fold, respectively, over a 90-fold dose increase. Mean terminal elimination half-life was 0.820–7.16 hours across doses. Renal excretion was negligible. Administration of soticlestat tablets, and with food, lowered \(C_{\text{max}}\) but did not affect overall exposure. Plasma 24HC concentrations generally decreased with increasing dose.

Conclusions: Soticlestat appeared to be well tolerated after a single oral administration of up to 1350 mg and dose-dependently reduced plasma 24HC concentrations. Systemic exposure increased in a greater than dose-proportional manner over the dose range evaluated but was not affected by formulation or administration with food.

Keywords
24S-hydroxycholesterol, cholesterol 24-hydroxylase inhibitor, epilepsy, NMDA signalling, pharmacokinetics
1 | INTRODUCTION

Approximately 50 million people worldwide have epilepsy.\(^1,2\) In the United States of America, epilepsy affects nearly 3.4 million Americans of all ages\(^3\) at an estimated annual cost of $17.6 billion in direct and indirect costs.\(^4\) Between 49 and 139 new cases of epilepsy are diagnosed annually per 100,000 population.\(^1\) Nearly a third of patients are refractory to available medications,\(^5\) and the National Institute of Neurological Diseases and Stroke has identified “an urgent need for novel chemical entities that will provide a greater likelihood of complete control of seizures in patients who are currently treatment resistant.”\(^6\)

**Cholesterol 24-hydroxylase** (CH24H), also known as CYP46A1, is a brain-specific enzyme responsible for cholesterol catabolism.\(^7-9\) Although CH24H is predominantly expressed in neurons in a normal state, non-clinical and human post-mortem studies have shown that neurodegeneration and brain insults lead to induction of CH24H expression in astrocytes and microglia.\(^10,11\) In particular, **24S-hydroxycholesterol** (24HC), the end-product of the reaction catalysed by CH24H, may have a neurotoxic liability, such as oxidative stress and necroptosis.\(^12-14\)

Importantly, 24HC is a positive allosteric modulator of **N-methyl-D-aspartate** (NMDA) receptor activity,\(^15\) suggesting that CH24H may play a role in disorders, such as some epilepsies, that are characterized by central glutamatergic overactivation. In particular, plasma 24HC levels are higher in children and adolescents than in adults,\(^16\) suggesting that 24HC could be a potential therapeutic target in children experiencing generalized tonic-clonic seizures observed in some developmental epileptic encephalopathies (DEE).\(^17\) This suggestion is based on experimental findings in rodents showing that blocking NMDA receptors using **NR2B** inhibitors would restrict the spatiotemporal spread of activity in the cortex.\(^18\)

Soticlestat is a novel small-molecule compound in development for epilepsy; it inhibits CH24H, reducing 24HC.\(^19\) It is known that 24HC binds to NR2B subunit of the NMDA receptor to enhance its functions cooperatively,\(^15\) so soticlestat was studied in several rodent models of epilepsy, showing its anti-epileptic effects mostly in non-focal epilepsy tests. In a mouse pentyleneetetrazol (PTZ)-induced kindling development model, dose-dependent effects of soticlestat in reducing the generalized seizure frequency were observed, showing a strong correlation with 24HC lowering.\(^20\) Furthermore, in a series of preclinical studies, soticlestat suppressed spontaneous convulsions in young APP/PS1-transgenic mice,\(^21\) reduced kainic-acid-induced neurodegeneration in the hippocampus,\(^22,23\) attenuated convulsions in PTZ-exposed rats\(^20\) and blocked audiogenic seizures in genetically susceptible young mice (unpublished data). Subsequently, non-clinical pharmacokinetic (PK), genotoxicity and toxicological studies of soticlestat were successfully performed in rats and dogs. Accordingly, soticlestat was identified as a promising therapeutic candidate with the potential to control seizures in difficult-to-treat patients with developmental epileptic encephalopathies.\(^24\)

This article describes two first-in-human (FIH), single, escalating-dose studies conducted to evaluate the safety, tolerability, PK, bioavailability, food effect and pharmacodynamics (PD) of soticlestat in healthy subjects.

2 | METHODS

For each study, the clinical study protocol, protocol amendments and informed consent forms were reviewed and approved by an Institutional Review Board. Both studies were performed in accordance with the principles of the Declaration of Helsinki and in compliance with the International Council on Harmonisation Guidelines for Good Clinical Practice at Celerion (Lincoln, NE, USA; Study TAK-935-101; NCT02201056) and Parexel (Glendale, CA, USA; Study TAK-935-1005; NCT02906813). All participants provided written informed consent before participation. Both studies were prospectively registered on the ClinicalTrials.gov database prior to enrolling the first subjects in each study.

2.1 | Single rising-dose study

A phase 1, randomized, double-blind, placebo-controlled, single-dose study was performed on six cohorts of eight subjects each. Six subjects were randomly assigned to a single dose of soticlestat (oral solution: 15, 50, 200, 600, 900 or 1350 mg) and two subjects to placebo after fasting overnight. The starting dose of 15 mg was based on the no-observed-adverse-effect level (NOAEL) in dogs (considered the more sensitive species) and the projected pharmacologically active dose/exposures in humans from the epileptic mouse model, per regulatory guidance.\(^25\) Using allometric scaling principles, applying a
10-fold safety factor, and adjusting for cross-species differences in protein binding and oral drug bioavailability, the selected 15 mg single dose was associated with a 44-fold safety margin from the dog NOAEL. The initially proposed maximal dose of 600 mg was selected to be several times the predicted pharmacologically active dose to identify doses that are safe to administer to humans, without exceeding the dog NOAEL exposure limits. Based on the favourable emerging safety and tolerability profile, and lower than predicted plasma exposure of soticlestat measured up to 600 mg, two additional doses of 900 mg and 1350 mg were studied.

A sentinel dosing approach was also used in this study, whereby initially only two subjects received soticlestat and one received placebo in each cohort. After the 24-hour postdose safety and tolerability data for these three subjects were reviewed and considered acceptable, the remaining five subjects in each cohort were administered study drug. Dose escalation decisions occurred after full review of the blinded safety, tolerability and PK data from the preceding cohort. After the first dose, dose escalation was limited to an escalated dose that was predicted to result in no greater than a three-fold increase in exposure of soticlestat measured up to 600 mg, two additional doses while providing sufficient safety margins for evaluating the effects of formulation or food on soticlestat PK. Eligible subjects (N = 9) were randomized in a 1:1:1 ratio to one of three sequences (ABC, BCA or CAB). Regimen A consisted of soticlestat 300 mg in tablet formulation (3 × 100 mg tablets) administered 30 minutes after starting ingestion of a high-fat meal; regimen B consisted of soticlestat 300 mg in tablet formulation (3 × 100 mg tablets) after a 10-hour fast; and regimen C consisted of a single 300 mg dose of soticlestat oral solution (10 mg/mL in sterile water with citric acid and polysorbate 80) administered after a 10-hour fast. For all regimens (A, B and C), no food was allowed within 4 hours postdose. Each treatment regimen was administered after a washout period of at least 3 days.

Blood samples (one 4 mL sample per scheduled time) for PK analysis of soticlestat and its metabolite M-I were collected at pre-dose (in the 30 minutes before dose administration) and at 0.17, 0.25, 0.33, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours after Day 1 dosing in each period.

### 2.2 Relative bioavailability and food-effect study

A phase 1, randomized, open-label, single-dose, three-way crossover study assessed the oral bioavailability of soticlestat 300 mg (administered as three 100 mg tablets) relative to a soticlestat 300 mg oral solution and assessed the effect of food on the bioavailability of soticlestat 300 mg when administered as tablets in healthy male and female adult subjects. A single dose of 300 mg was selected on the basis that it is expected to fall within the efficacious dose range, while providing sufficient safety margins for evaluating the effects of formulation or food on soticlestat PK. Eligible subjects (N = 9) were randomized in a 1:1:1 ratio to one of three sequences (ABC, BCA or CAB). Regimen A consisted of soticlestat 300 mg in tablet formulation (3 × 100 mg tablets) administered 30 minutes after starting ingestion of a high-fat meal; regimen B consisted of soticlestat 300 mg in tablet formulation (3 × 100 mg tablets) after a 10-hour fast; and regimen C consisted of a single 300 mg dose of soticlestat oral solution (10 mg/mL in sterile water with citric acid and polysorbate 80) administered after a 10-hour fast. For all regimens (A, B and C), no food was allowed within 4 hours postdose. Each treatment regimen was administered after a washout period of at least 3 days.

### 2.3 Safety evaluation

Safety was evaluated throughout both studies by monitoring for adverse events (AEs) and by performing clinical laboratory tests, vital sign measurements, 12-lead electrocardiograms (ECGs) and physical examinations.

Samples for clinical laboratory tests were collected after subjects had fasted for at least 10 hours overnight and in accordance with acceptable laboratory procedures. Vital signs included oral temperature, respiration rate, heart rate and blood pressure.

### 2.4 Pharmacokinetic and pharmacodynamic analyses

Concentrations of soticlestat and its metabolite M-I were measured in plasma and urine by high-performance liquid chromatography with tandem mass spectrometry detection (HPLC-MS/MS). The analytes and their internal standards were extracted from human plasma or urine (50 μL) by a solid phase extraction procedure or by dilution, respectively, and detected by multiple reaction monitoring. Both assays were validated with a concentration range of 1.00 ng/mL (lower limit of quantitation [LLOQ]) to 2000 ng/mL (upper limit of quantitation [ULOQ]) for both soticlestat and its metabolite M-I.
Plasma 24HC levels were measured by HPLC-MS/MS within a validated concentration range of 2.00 ng/mL (LLOQ) to 100 ng/mL (ULOQ). Following incubation in sodium hydroxide and methanol, the analyte and its internal standard were extracted from human plasma (500 µL) by a liquid–liquid extraction procedure and detected by multiple reaction monitoring.

For all above-mentioned assays, intra-assay accuracy and precision were evaluated for each plasma (or urine) quality control (QC) pool by multiple analyses (n = 6) of the pool in one run. Acceptance criteria were met with accuracy within ±15% (±20% for LLOQ) of the nominal value for each QC level and %CV ≤ 15% for each QC level (≤ 20% for LLOQ). Similarly, inter-assay accuracy and precision were achieved from the plasma (or urine) QC pools (n = 6) in three validation runs over three separate days.

The PK and PD parameters were estimated from plasma or urine concentration–time data using standard non-compartmental analysis methods with Phoenix WinNonlin™ version 6.3 (Certara, Princeton, NJ, USA). Plasma PK parameters included area under the plasma concentration–time curve from zero to the time of the last quantifiable concentration (AUC[0-t]), area under plasma concentration-time curve from zero to infinity (AUC[∞]), maximum plasma concentration (Cmax), apparent plasma clearance of drug after extravascular administration (CL/F), terminal elimination half-life (t1/2), apparent volume of distribution during the terminal phase after extravascular administration (V/F), and metabolic ratio (MR; calculated as [AUC∞ (M-I) × soticlestat molecular weight] / [AUC∞ (soticlestat) × M-I molecular weight])−1. Urine PK parameters included cumulative amount of drug excreted unchanged in urine from zero to 96 hours (AUEC96), fraction of dose excreted unchanged into urine (fU; for soticlestat only) and renal clearance of drug (ClR). Plasma PD parameters included area under the effect–time curve from zero to 24 hours (AUEC24; baseline and post-dose), area under the effect–time curve from zero to 96 hours (AUEC96; post-dose), observed effect at 24 hours (E24; baseline and post-dose), percent change from time-matched baseline for AUEC24 and percent change from time-matched baseline for E24.

2.5 | Statistical analysis

All data analyses were performed using SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA). Data for PK parameters for soticlestat and its metabolite M-I, and PD parameters for plasma 24HC are presented using descriptive statistics throughout. Dose proportionality for Cmax and AUC was assessed using the Power model. Increases in Cmax, AUC[0-t], and AUC[∞] were considered to be dose-proportional if the 90% confidence interval (CI) for the slope of the log-transformed dose and PK parameter was within the range of 0.95–1.05. The effect of dose on tmax and terminal rate constant (λz) was assessed using an analysis of variance (ANOVA) model with dose level as a fixed factor.

In the bioavailability study, ANOVA was performed on natural logarithms of soticlestat Cmax and AUC with factors of sequence, subject nested within sequence, period and regimen. The factor of subject nested within sequence was a random effect, and other factors are fixed effects. Within the framework of ANOVA, pairwise comparisons were performed to assess the relative bioavailability of soticlestat and M-I for the tablet formulation relative to the oral solution formulation via point estimates of the central value ratios of two formulations and their 90% CIs for Cmax and AUC. The effect of food on the bioavailability of soticlestat tablet formulation (after a high-fat meal vs in a fasted state) were evaluated via point estimates of the central value ratios of fed/fasting conditions and their 90% CIs for Cmax and AUC for soticlestat and M-I.

AEs were summarized as the number and percentage of subjects who experienced at least one AE.

2.6 | Nomenclature of targets and ligands

All molecular target nomenclature conforms to the IUPHAR/BPS guide to pharmacology nomenclature classification. Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20.

3 | RESULTS

In total, 48 subjects were enrolled in the single rising-dose study in a total of six cohorts and were randomly assigned to treatment or placebo. Nine subjects were enrolled in the relative bioavailability and food-effect study. All subjects completed the studies. Subject demographics are presented in Table 1.

3.1 | Safety and tolerability of soticlestat

Single doses of soticlestat ranging from 15 mg to 1350 mg administered as an oral solution appeared to be well tolerated. Five (41.7%) of the 12 subjects who received placebo and 14 (38.9%) of the 36 who received soticlestat reported a total of 13 and 29 treatment-emergent AEs (TEAEs), respectively. The incidence of individual TEAEs in subjects who received soticlestat did not appear to be dose-dependent.

The most frequently reported TEAEs were headache (placebo, n = 2; soticlestat, n = 3), ECG electrode application-site dermatitis (soticlestat, n = 2) and nausea (soticlestat, n = 2). All TEAEs were considered by the investigator to be mild in intensity. No deaths, other serious or severe AEs or AEs leading to study drug or study visit discontinuation were reported. No clinically significant abnormalities in clinical laboratory tests (including hormone levels), or changes from baseline in vital signs, physical examinations, comprehensive eye examinations or ECG measurements were observed during the study at all doses.
TABLE 1  Subject demographics and baseline characteristics

| Characteristic         | SRD                              | rBA/FE                         |
|------------------------|----------------------------------|--------------------------------|
|                        | Placebo (n = 12)                 | Soticlestat (all arms) (n = 36) | Total (N = 48)                 | Total (N = 9)                 |
| Age, mean (SD), years  | 35.9 (10.41)                     | 32.8 (10.10)                   | 33.6 (10.15)                   | 36.7 (8.00)                   |
| Sex, n (%)             |                                  |                                |                                |                              |
| Male                   | 7 (58.3)                         | 19 (52.8)                      | 26 (54.2)                      | 7 (77.8)                      |
| Female                 | 5 (41.7)                         | 17 (47.2)                      | 22 (45.8)                      | 2 (22.2)                      |
| Race, n (%)            |                                  |                                |                                |                              |
| White                  | 10 (83.3)                        | 29 (80.6)                      | 39 (81.3)                      | 3 (33.3)                      |
| Black or African American | 2 (16.7)                         | 6 (16.7)                       | 8 (16.7)                       | 5 (55.6)                      |
| Multiracial            | 0                               | 1 (2.8)                        | 1 (2.1)                        | 1 (11.1)                      |
| Ethnicity, n (%)       |                                  |                                |                                |                              |
| Hispanic or Latino     | 1 (8.3)                          | 3 (8.3)                        | 4 (8.3)                        | 2 (22.2)                      |
| Non-Hispanic or -Latino | 11 (91.7)                       | 33 (91.7)                      | 44 (91.7)                      | 7 (77.8)                      |
| Height, mean (SD), cm  | 170.8 (5.99)                     | 169.9 (9.16)                   | 170.1 (8.43)                   | 171.1 (3.44)                  |
| Weight, mean (SD), kg  | 70.2 (10.48)                     | 73.9 (12.70)                   | 73.0 (12.18)                   | 77.6 (9.04)                   |
| BMI, mean (SD), kg m⁻² | 24.0 (2.53)                      | 25.5 (3.16)                    | 25.1 (3.06)                    | 26.5 (2.43)                   |

Abbreviations: BMI, body mass index; rBA/FE, relative bioavailability and food-effect study; SD, standard deviation; SRD, single rising-dose study.

3.2  Pharmacokinetics of soticlestat

Mean plasma soticlestat Cₘₐₓ ranged from 43.5 ng/mL for the 15 mg dose to 7950 ng/mL for the 1350 mg dose (Table 2). Median tₘₐₓ was between 0.25 hours and 0.52 hours for all soticlestat doses (15–1350 mg) (Table 2). A second smaller peak was observed at approximately 8 hours post-dose for all doses (Figure 1).

Mean AUCₘₐₓ (% coefficient of variation [%CV]) ranged from 23.3 (28.8) ng·h/mL for the 15 mg dose to 13 500 (42.6) ng·h/mL for the 1350 mg dose (Table 2). Similar results were observed for AUC₀₋ₜ (33.3 [86.9] ng·h/mL and 13 500 [42.8] ng·h/mL, respectively). Mean t₁/₂z for soticlestat ranged from 0.820 hours to 7.16 hours (Table 2), although t₁/₂z estimates at the lower doses of 15 mg and 50 mg must be viewed with caution because soticlestat levels rapidly dropped below the LLOQ. Mean CL/F for soticlestat decreased with increasing soticlestat dose from 689 L/h with 15 mg dosing to 112 L/h with 1350 mg dosing (Table 2). Mean V₁/F ranged from 732 to 2240 L, but no dose-related trend was apparent (Table 2).

The estimated slopes (90% CI) for the relationship between log-transformed soticlestat PK parameters and log-transformed soticlestat doses were 1.22 (1.11, 1.32), 1.38 (1.28, 1.48) and 1.42 (1.31, 1.53) for Cₘₐₓ, AUC₀₋ₜ and AUCₘₐₓ, respectively. All estimated slopes failed to meet the pre-specified criteria for dose proportionality and were significantly higher than 1 (P < .001 for all).

Mean plasma M-I concentrations increased with increasing soticlestat dose with a Cₘₐₓ at approximately 0.5–1 hours after soticlestat administration, followed by a relatively fast decline (Table 3).

Renal excretion of soticlestat was negligible. Only approximately 0.05–0.6% of each soticlestat dose was excreted in urine, and CLᵣ was only 0.230–0.620 L/h (Table 2). In contrast, CLᵣ of M-I was higher at 3.23–4.76 L/h (Table 3).

The oral solution and tablet formulations for soticlestat offered similar plasma concentration–time profiles with a 300 mg dose. Plasma soticlestat concentrations for the tablet formulation were only slightly lower than for the oral solution 16 hours post-dose. A secondary peak in plasma soticlestat levels was observed approximately 10 hours post-dose with both the oral solution and tablet formulations.

Soticlestat Cₘₐₓ was 36.9% lower with the tablet than with the oral solution formulation, but AUCₘₐₓ was only 15.8% lower (Table 4). Median tₘₐₓ was also delayed from 0.35 hours with the oral solution to 0.53 hours with the tablet. No difference in t₁/₂z was observed between the oral solution and oral tablet formulations (mean [%CV]; 4.29 [33.5] h and 4.13 [38.5] h, respectively).

In the food-effect study, after reaching Cₘₐₓ, plasma concentrations of soticlestat tablet under fed conditions were slightly higher than the levels reported under fasting conditions up to 10 hours post-dose. Plasma concentrations were comparable between fasting and fed conditions from 10 hours post-dose (Figure 2). A secondary peak in plasma soticlestat concentration was observed approximately 10 hours post-dose under both fasting and fed conditions but was slightly more apparent under fasting conditions. AUCₘₐₓ for soticlestat when administered as an oral tablet under fed conditions was only 10.6% lower than that under fasting conditions (Table 4). Compared with under fasting conditions, median tₘₐₓ under fed conditions was delayed from 0.53 hours to 2.00 hours, and the corresponding soticlestat Cₘₐₓ decreased by 59.7% under fed conditions (Table 4). After a single-dose administration of 300 mg soticlestat oral tablets, mean (%CV) soticlestat t₁/₂z values were similar under fasting or fed conditions (4.13 [38.5] hours and 5.00 [61.7] hours, respectively).
### TABLE 2  Summary of plasma and urine PK parameters of soticlestat after administration of a single oral dose in healthy subjects

| Soticlestat plasma PK parameters | 15 mg (n = 6) | 50 mg (n = 6) | 200 mg (n = 6) | 600 mg (n = 6) | 900 mg (n = 6) | 1350 mg (n = 6) |
|---------------------------------|--------------|--------------|----------------|----------------|---------------|---------------|
| C<sub>max</sub>, mean (%CV), ng/mL | 43.5 (94.7)  | 210 (72.8)   | 571 (45.1)     | 4552 (56.5)    | 5080 (35.5)   | 7953 (27.0)   |
| t<sub>max</sub>, median (range), h | 0.25 (0.25–0.25) | 0.25 (0.25–0.50) | 0.25 (0.23–0.50) | 0.52 (0.25–1.00) | 0.50 (0.50–1.48) | 0.50 (0.50–1.00) |
| AUC<sub>0–t</sub>, mean (%CV), ng h/mL | 33.3 (86.9) | 169 (52.4) | 563 (35.0) | 5790 (59.2) | 7620 (25.3) | 13 500 (42.8) |
| AUC<sub>∞</sub>, mean (%CV), ng h/mL | 23.3 (28.8)<sup>a</sup> | 172 (62.1)<sup>b</sup> | 621 (38.7)<sup>a</sup> | 5810 (59.0) | 7660 (25.6) | 13 500 (42.6) |
| t<sub>1/2</sub>, mean (%CV), h | 0.820 (82.8)<sup>a</sup> | 2.99 (68.8)<sup>a</sup> | 4.39 (43.3)<sup>a</sup> | 4.77 (53.8) | 7.16 (34.3) | 5.31 (21.3) |
| V<sub>A</sub>/F, mean (%CV), L | 732 (62.3)<sup>a</sup> | 1500 (49.6)<sup>a</sup> | 2240 (50.1)<sup>a</sup> | 993 (69.7) | 1230 (26.3) | 852 (34.0) |
| CL/F, mean (%CV), L/h | 689 (33.9)<sup>a</sup> | 549 (112.4)<sup>b</sup> | 355 (37.4)<sup>a</sup> | 145 (64.3) | 124 (25.4) | 112 (34.7) |

| Soticlestat urine PK parameters | 15 mg (n = 6) | 50 mg (n = 6) | 200 mg (n = 6) | 600 mg (n = 6) | 900 mg (n = 6) |
|---------------------------------|--------------|--------------|----------------|----------------|---------------|
| CL<sub>r</sub>, mean (%CV), L/h | 0.280 (33.3) | 0.230 (35.4) | 0.360 (27.0) | 0.320 (39.1) | 0.440 (38.0) |
| f<sub>e</sub>, mean (%CV) | 0.0500 (39.2) | 0.0700 (46.6) | 0.100 (27.4) | 0.360 (91.8) | 0.400 (57.8) |

Values rounded to three significant figures, except for t<sub>max</sub> presented as two decimal places.

Abbreviations: AUC<sub>∞</sub>, area under plasma concentration–time curve from zero to infinity; AUC<sub>0–t</sub>, area under the plasma concentration–time curve from zero to the time of the last quantifiable concentration; CL/F, apparent plasma clearance of drug after extravascular administration; CL<sub>r</sub>, renal clearance of drug; C<sub>max</sub>, maximum plasma concentration; CV, coefficient of variation; f<sub>e</sub>, fraction of dose excreted unchanged into urine; PK, pharmacokinetic; t<sub>1/2</sub>, terminal elimination half-life; t<sub>max</sub>, time to maximum plasma concentration; V<sub>A</sub>/F, apparent volume of distribution during the terminal phase after extravascular administration.

<sup>a</sup>N = 3;
<sup>b</sup>N = 4.
3.3 | Pharmacodynamics of soticlestat

At baseline (Day 0), mean plasma 24HC concentrations generally fluctuated from 40 ng/mL to 55 ng/mL across the placebo and soticlestat groups (Figure 3). No difference in mean plasma 24HC concentrations was apparent between the placebo group and soticlestat 15 mg group, but mean plasma 24HC concentrations trended lower in the soticlestat 50–1350 mg groups (Figure 3). The magnitude of any decrease in 24HC levels from Days 1 to 4 post-dose appeared to be greater with increasing dose (Figure 3C).

For the 50, 200 and 600 mg groups, maximum reductions in 24HC levels were observed approximately 16 hours post-dose, and approximately 48 hours post-dose in the 900 and 1350 mg groups (Figure 3A and 3C). 24HC levels returned to baseline levels by 96 hours post-dose in all groups (Figure 3C). Time-matched analyses over the first 24 hours following soticlestat administration also showed a maximum mean decrease in plasma 24HC concentration of approximately 23% at 16 hours for the 900 mg group (Figure 3B).

Dose-dependent decreases in E$_{24}$, AUEC$_{24}$ and AUEC$_{96}$ estimates were also observed, with an estimated maximum decrease in mean AUEC$_{96}$ of approximately 28.7% vs placebo observed with the 900 mg dose. The time-matched maximum mean change was approximately 21% for E$_{24}$ and 14% for AUEC$_{24}$.

4 | DISCUSSION

Single oral doses of soticlestat ranging from 15 mg to 1350 mg appeared to be generally well tolerated when administered as an oral solution or tablet to healthy subjects in a fasting or fed state. All AEs were mild in intensity, no dose-limiting toxicities were observed and no subjects experienced AEs leading to study drug or study visit discontinuation. Accordingly, the full planned dose range of this study was investigated, and the PK and PD profiles of soticlestat were characterized. Furthermore, compared with the observed exposure (area under the plasma concentration–time curve from zero to 24 hours [AUC$_{24}$] = 700 ng·h/mL) at the minimal
efficacious dose in an epileptic mouse model (unpublished data), similar mean soticlestat exposure ($AUC_{\infty}$) was reached with a 200 mg dose of soticlestat (621 ng h/mL) and was approximately 19-fold higher than that with the 1350 mg dose (13 500 ng h/mL), suggesting that therapeutic dosing can be achieved with an acceptable safety and tolerability profile.

### Table 3

Summary of plasma and urine PK parameters of the soticlestat metabolite M-I after administration of a single oral dose in healthy subjects

| Parameter | Soticlestat 15 mg (n = 6) | Soticlestat 50 mg (n = 6) | Soticlestat 200 mg (n = 6) | Soticlestat 600 mg (n = 6) | Soticlestat 900 mg (n = 6) | Soticlestat 1350 mg (n = 6) |
|-----------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| **M-I plasma PK parameters** | | | | | | |
| $C_{\text{max}}$, mean (%CV), ng/mL | 19.3 (34.4) | 56.4 (66.1) | 151 (35.9) | 542 (23.6) | 833 (13.2) | 900 (19.8) |
| $t_{\text{max}}$, median (range), h | 0.50 (0.25–1.98) | 0.38 (0.25–0.50) | 0.50 (0.48–0.53) | 0.53 (0.50–1.00) | 1.00 (0.50–1.50) | 1.25 (0.98–1.50) |
| $AUC_{(0-t)}$, mean (%CV), ng h/mL | 39.1 (43.5) | 114 (55.1) | 293 (26.5) | 1490 (31.8) | 2710 (17.1) | 3110 (18.3) |
| $AUC_{\infty}$, mean (%CV), ng h/mL | 45.8 (37.0)# | 118 (53.6) | 299 (25.9) | 1500 (31.7) | 2780 (18.0)# | 3120 (18.2) |
| $t_{1/2z}$, mean (%CV), h | 1.59 (29.2)# | 1.44 (10.8) | 2.92 (32.3) | 3.64 (45.7) | 7.82 (52.6)# | 4.45 (47.7) |
| MR (based on $AUC_{\infty}$), mean (%CV) | 1.84 (42.9)c | 0.750 (30.0)d | 0.580 (24.4)c | 0.300 (37.6) | 0.340 (22.8)a | 0.240 (32.6) |

### Table 4

Plasma PK parameters after administration of a single 300 mg soticlestat dose (oral tablet vs oral solution [fasted], and oral tablet [fed] vs oral tablet [fasted])

| Parameter | Regimen A (fed) | Regimen B (fasted) | Regimen C (solution, fasted) |
|-----------|----------------|-------------------|-----------------------------|
| $C_{\text{max}}$, ng/mL | 9.690 (9.531) | 6.903 (6.733) | 7.363 (7.290) |
| $AUC_{(0-t)}$, ng h/mL | 7.139 (7.002) | 7.301 (7.152) | 7.309 (7.230) |
| $AUC_{\infty}$, ng h/mL | 7.144 (7.012) | 7.315 (7.165) | 7.314 (7.163) |

Values rounded to three significant figures except for $t_{\text{max}}$ presented as two decimal places.

Abbreviations: $AUC_{\infty}$, area under plasma concentration–time curve from zero to infinity; $AUC_{(0-t)}$, area under the plasma concentration–time curve from zero to the time of the last quantifiable concentration; $C_{\text{max}}$, maximum plasma concentration; MR, metabolic ratio; PK, pharmacokinetic; $t_{1/2z}$, terminal elimination half-life; $t_{\text{max}}$, time to maximum plasma concentration.

#N = 5;  
#MR = ($AUC_{\text{M-I}}$) / ($AUC_{\text{soticlestat}}$) × (soticlestat molecular weight) / (M-I molecular weight);  
#N = 3;  
#N = 4.

---

19-fold higher than that with the 1350 mg dose (13 500 ng h/mL), suggesting that therapeutic dosing can be achieved with an acceptable safety and tolerability profile.
Soticlestat oral solution was rapidly absorbed with a median $t_{\text{max}}$ of 0.25–0.52 hours post-dose, which was soon followed by the plasma $C_{\text{max}}$ for M-I at 0.5–1 hours. Soticlestat was eliminated from plasma with a mean $t_{1/2}$ of approximately 4–7 hours, although the accuracy of $t_{1/2}$ could not be adequately characterized at the lower doses of soticlestat because plasma levels rapidly dropped below the LLOQ. Exposure to soticlestat increased in a greater than dose-proportional manner over the 15–1350 mg dose range, indicating a nonlinear PK profile that may warrant attention when multiple-dose studies are performed. It was noted that the apparent CL/F values of soticlestat decreased as dose increased, although $V_z/F$ did not show dose-related trends, suggesting that drug absorption (i.e., bioavailability) rather than drug disposition (i.e., metabolism and excretion) might be affected by dose.

Renal excretion of the parent drug soticlestat was limited, with no more than 0.6% of soticlestat being recovered in urine, suggesting a minor contribution to soticlestat elimination. This is consistent with the metabolite profiling from animal and in vitro studies, indicating that the major route of elimination of soticlestat is via hepatic metabolism. Glucuronidation is the major metabolic pathway for soticlestat in human hepatocytes, with oxidation playing a minor role.

The circulating N-oxide metabolite of soticlestat (M-I) identified in preclinical studies was measured in human plasma with a mean metabolic ratio (based on AUC$_{\infty}$) of 1.84 to 0.240, generally decreasing over the soticlestat dose range of 15–1350 mg, which is consistent with the observed greater than dose-proportional increase in soticlestat plasma exposures. Given the weak potency of M-I, as shown by an approximate 200-fold higher IC$_{50}$ value than soticlestat in an in vitro assay on human CH24H activity, M-I is expected to contribute negligibly to the PD effects of soticlestat.

The AUC for the oral tablet formulation was comparable to that of the oral solution for a single 300 mg dose of soticlestat, whereas $C_{\text{max}}$ was approximately 37% lower, as may be expected when absorption is slowed by a tablet versus solution formulation. Coadministration with food also had little impact on the AUC of the soticlestat tablet but further delayed oral absorption ($t_{\text{max}}$ 2.00 h vs 0.500 h) and lowered the $C_{\text{max}}$ by nearly 60%. The lower $C_{\text{max}}$ with the tablet formulation, and when administered with food, may need to be considered when selecting dosages for further studies to ensure that potentially therapeutic concentrations are being achieved and maintained, while potentially avoiding the risk of greater than dose-proportional drug accumulation with high doses. However,
as total systemic exposure (AUC) remained nearly unchanged, the effectiveness of soticlestat is not expected to be compromised. Thus, it has been concluded that administration of soticlestat oral tablets independently of meals is feasible.

After soticlestat single-dose administration, plasma 24HC concentrations decreased in a dose-dependent manner, indicating that soticlestat likely reached and interacted with the target enzyme, CH24H, in brain tissue. Time-matched percentage change from baseline in 24HC plasma concentrations over a 24-hour interval, controlled for the potential influence of circadian rhythm, showed a maximum decrease of 23% at 16 hours post-dose after a single 900 mg dose of soticlestat. The corresponding maximum decrease in $E_{24}$ and $AUEC_{24}$ was approximately 21% and 14%, respectively. Given that the nadir following this relatively high dose was observed as late as 48 hours post-dose, which is considerably delayed compared with the median $t_{\text{max}}$ of 0.25–0.52 hours for soticlestat in plasma, these time-matched estimates from a 24-hour sampling period should be interpreted with some caution. However, the observed lag between $C_{\text{max}}$ and a PD response is typical of drugs that act through an indirect mechanism of action, in which time to maximal response is dose-dependent and delayed at larger doses.\textsuperscript{28–30}

These initial observations after single-dose treatment are to be investigated further following multiple daily dosing to optimize soticlestat dosing regimen. Of note, while cerebrospinal fluid samples were not collected in this FIH study, positron emission tomography (PET) imaging conducted in healthy subjects demonstrated that single, oral doses of 50 to 600 mg of soticlestat were centrally penetrant and led to specific CH24H enzyme occupancy in a dose- and time-dependent manner, thus establishing the strong relationship between soticlestat exposure and target engagement in humans.\textsuperscript{31} Taking these data together, a population PK/PD modelling effort is currently underway to describe the relationships between dose and exposures of soticlestat, PET-derived CH24H enzyme occupancy in the brain, and reduction in 24HC plasma levels using pooled data from multiple clinical studies to support rational dose selection for subsequent studies in patients following chronic treatment with soticlestat.\textsuperscript{32}

In conclusion, soticlestat was well tolerated after a single oral administration of up to 1350 mg in healthy subjects with greater than dose-proportional increase in systemic exposure observed over the dose range evaluated and a dose-dependent decrease in the plasma 24HC concentrations, indicative of central target engagement and downstream PD effects. Administration of soticlestat as a tablet formulation, or in combination with food, decreased $C_{\text{max}}$ but did not affect overall drug exposure compared with administration as an oral solution.

**ACKNOWLEDGEMENTS**

The authors wish to thank Ronald Lee, Minh Vo, Jinhui Xie, Jane Li, Thomas Misko and Joanna Segieth for their contribution to the progression of the soticlestat project. All studies were funded by the sponsor, Takeda Pharmaceutical Company, Ltd. Editorial support was...
provided by Oxford PharmaGenesis, Oxford, UK, with funding from Takeda Pharmaceutical Company, Ltd. Editorial support was provided by Oxford PharmaGenesis, Oxford, UK, with funding from Takeda Pharmaceutical Company, Ltd.

COMPETING INTERESTS
S.W., M.C. and H.F. are employees of Takeda Pharmaceutical Limited Company and own stock or stock options. G.C., E.M.P. and J.A. are former employees of Takeda and own stock or stock options.

CONTRIBUTORS
All authors contributed to the study conception and design. Data (PK and PD) analyses were performed by the Quantitative Clinical Pharmacology group at Takeda. All authors were involved in manuscript preparation and review. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT
The datasets, including the redacted study protocol, redacted statistical analysis plan, and de-identified individual participants data supporting the results reported in this article, will be available 3 months after the submission of a request, to researchers who provide a methodologically sound proposal. The data will be provided after its de-identification, in compliance with applicable privacy laws, data protection and requirements for consent and anonymization.

ORCID
Hélène Faessel https://orcid.org/0000-0002-3007-3345

REFERENCES
1. World Health Organization. Epilepsy facts. http://www.who.int/mediacentre/factsheets/fs999/en/. Accessed 31 July 2020.
2. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459-480.
3. Zack MM, Kobau R. National and state estimates of the numbers of adults and children with active epilepsy—United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(31):821-825.
4. Epilepsy Foundation. Incidence and prevalence: epilepsy and seizure statistics. http://www.epilepsy.com/learn/epilepsy-statistics. Accessed 31 July 2020.
5. Centers for Disease Control and Prevention. Targeting epilepsy: Improving the lives of people with one of the nation’s most common neurological conditions at a glance 2011. http://www.cdc.gov/chronicdisease/resources/publications/AAG/epilepsy.htm. Accessed 31 July 2020.
6. National Institute of Neurological Disorders and Stroke. Epilepsy research benchmarks progress report 2007–2012. http://www.ninds.nih.gov/research/epilepsyweb/benchmarks_2007-2012progress.pdf. Accessed 31 July 2020.
7. Xie C, Lund EG, Turley SD, Russell DW, Dietschy JM. Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration. J Lipid Res. 2003;44(9):1780-1789.
8. Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, Russell DW. Knock-out of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem. 2003;278(25):22980-22988.
9. Russell DW, Halford RW, Ramirez DM, Shah R, Kotti T. Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain. Annu Rev Biochem. 2009;78(1):1017-1040.
10. Cartagena CM, Ahmed F, Burns MP, et al. Cortical injury increases cholesterol 24S hydroxylase (Cyp46) levels in the rat brain. J Neurotrauma. 2008;25(9):1087-1098.
11. Bogdanovic N, Breillon L, Lund EG, et al. On the turnover of brain cholesterol in patients with Alzheimer’s disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in gial cells. Neurosci Lett. 2001;314(1-2):45-48.
12. Nury T, Zarrour A, Mackrill JJ, et al. Induction of oxioapoptophagy on 15SN murine oligodendrocytes treated by 7-ketocholesterol, 7beta-hydroxycholesterol, or 24(S)-hydroxycholesterol: protective effects of alpha-tocopherol and docosahexaenoic acid (DHA; C22:6 n-3). Steroids. 2015;89(Pt B):194-203.
13. Noguchi N, Saito Y, Urano Y. Diverse functions of 24(S)-hydroxycholesterol in the brain. Biochim Biophys Res Commun. 2014;446(3):692-696.
14. Vo DK, Urano Y, Takabe W, Saito Y, Noguchi N. 24(S)-Hydroxycholesterol induces RIPK1-dependent but MLKL-independent cell death in the absence of caspase-8. Steroids. 2015;99(Pt B):230-237.
15. Paul SM, Doherty JJ, Robichaud AJ, et al. The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors. J Neurosci. 2013;33(44):17290-17300.
16. Breillon L, Lütjohann D, Stähle L, et al. Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. J Lipid Res. 2000;41(5):840-845.
17. Li D, Yuan H, Ortiz-Gonzalez XR, et al. GRIN2D recurrent de novo dominant mutation causes a severe epileptic encephalopathy treatable with NMDA receptor channel blockers. Am J Hum Genet. 2016;99(4):802-816.
18. Bandyopadhyay S, Hablitz JJ. NR2B antagonists restrict spatiotemporal spread of activity in a rat model of cortical dysplasia. Epilepsy Res. 2006;72(2-3):127-139.
19. Koike T, Miyamoto M, Nishi T, et al. Evaluation of pharmacodynamic effects of cholesterol 24-hydroxylase inhibitor TAK-935 and its target engagement in animals. Neurology. 2018;90(15 Supplement):P5.263.
20. Nishi T, Fujimoto S, Hasegawa S, Watanabe S, Kondo S. Inhibition of cholesterol 24-hydroxylase is a novel pharmacological strategy for epilepsy treatment. Neurology. 2018;90(15 Supplement):P5.264.
21. Nishi T, Watanabe S, Hasegawa S et al. Inhibition of cholesterol 24-hydroxylase improves the survival of a mouse model of epileptic phenotype and modulates extracellular levels of glutamate. In: Neuroscience 2018, San Diego, CA, USA, 2018. https://www.abstractsonline.com/pp8/#!/4649/presentation/25583
22. Hasegawa S, Nishi T, Watanabe S, Fujimoto S, Kondo S. Cholesterol 24-hydroxylase inhibition is a novel pharmacological mechanism that exerts neuroprotective effects against glutamate excitotoxicity in rats. In: Neuroscience 2018, San Diego, CA, USA, 2018. https://www.abstractsonline.com/pp8/#!/4649/presentation/25584
23. Salamone A, Terrone G, Raimondi Cominesi S, et al. Cholesterol 24-hydroxylase inhibition during epileptogenesis delays epilepsy onset and blocks seizures progression in a temporal lobe epilepsy. Epilepsia. 2018;59:S63-S64.
24. Blaler M, Johannessen S, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the Fourteenth Elat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in
preclinical and early clinical development. Epilepsia. 2018;59(10):1811-1841.

25. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. In: FDA Guidance Documents, 2005.

26. Alexander SPH, Mathie A, Peters JA, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Br J Pharmacol. 2019;176(Suppl 1):S142-S228.

27. Alexander SPH, Fabbro D, Kelly E, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. Br J Pharmacol. 2019;176(Suppl 1):S297-S396.

28. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21(4):457-478.

29. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther. 1994;56(4):406-419.

30. Sharma A, Jusko WJ. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol. 1998;45(3):229-239.

31. Tauscher J, Cole PE, Brown T, et al. A PET study with [18F]MNI-792 to determine cholesterol 24S-hydroxylase occupancy of TAK-935 in healthy subjects. J Cereb Blood Flow Metab. 2019;39(Suppl 1):524-608.

32. Wagner T, Tsai M, Chen G et al. Clinical trial simulations using a pharmacokinetic/enzyme-occupancy/pharmacodynamic model of TAK-935, a cholesterol 24S-hydroxylase inhibitor. American Epilepsy Society Annual Meeting 2017; Abst. 1.038.

How to cite this article: Wang S, Chen G, Merlo Pich E, Affinito J, Cwik M, Faessel H. Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects. Br J Clin Pharmacol. 2021;87(11):4354-4365. https://doi.org/10.1111/bcp.14854